This happened because the prescription of IL-23 inhibitors for the treatment of psoriasis renewed the problem of potential tuberculosis reactivation, based on the possibility that IL-23 antagonism does carry the same risk of tuberculosis reactivation as TNF-α inhibitors do, based on preclinical studies that have indicated that IL-23 has a potential role against tuberculosis infection [39]. This evidence concerns the gene TNF and tuberculosis.